Table 2.
Impact of study characteristics on prevalence estimates for lipohypertrophy in diabetes mellitus patients: Subgroup analyses
| Subgroup analysis | n | 95% CI | I 2 (%) | P‐value |
|---|---|---|---|---|
| Sample size | ||||
| <200 | 8 | 0.40 (0.30–0.49) | 89.1 | 0.000a |
| ≥200 | 18 | 0.37 (0.26–0.47) | 99.4 | 0.000a |
| Overall quality | ||||
| <3 points (low quality) | 4 | 0.43 (0.28–0.57) | 92.8 | 0.000a |
| ≥3 points (high quality) | 22 | 0.37 (0.27–0.46) | 99.2 | 0.000a |
| Publication year | ||||
| 1990s | 3 | 0.34 (0.19–0.48) | 94.5 | 0.000a |
| 2000s | 6 | 0.32 (0.16–0.49) | 98.9 | 0.000a |
| 2010– | 17 | 0.40 (0.32–0.48) | 98.5 | 0.000a |
| Country of origin | ||||
| Europe | 14 | 0.37 (0.25–0.49) | 98.8 | 0.000a |
| Asia | 9 | 0.41 (0.27,0.55) | 99.0 | 0.000a |
| Africa | 1 | – | ||
| North America | 1 | – | ||
| Mixed | 1 | – | ||
| DM type | ||||
| T1DM | 10 | 0.34 (0.19–0.49) | 98.6 | 0.000a |
| T2DM | 3 | 0.49 (0.23–0.74) | 99.4 | 0.000a |
| T1DM and T2DM | 10 | 0.37 (0.25–0.48) | 98.3 | 0.000a |
| NS | 3 | 0.41 (0.29–0.54) | 96.6 | 0.000a |
a
P < 0.001. I 2 ≥25% (low), ≥50% (moderate), ≥75% (high). CI, confidence interval; DM, diabetes mellitus; LH, lipohypertrophy; NS, not stated; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.